Repatha Now Available for Approximately 60% Off List Price

Repatha (evolucumab) is now avaliable at a discounted cash price through Amgen's new direct-to-patient program, AmgenNow, and through GoodRx, according to today’s news release.

Repatha is now available for a cash price of $239 a month, which is approximately 60% lower than the current list price in the United States, which is $572.70. This offer is available to all patients, including those who are on Medicare, Medicaid or are uninsured. It is available at the more than 70,000 participating GoodRx pharmacies nationwide. Amgen also plans to make Repatha available through the TrumpRx website.

“GoodRx is serving as the digital storefront to make Repatha more accessible for patients, leveraging our extensive retail pharmacy network to ensure it’s available where they already fill their prescriptions,” Laura Jensen, COO and President of Pharma Solutions at GoodRx, said in a news release. “This combination of meaningful savings and broad distribution helps break down barriers so patients can start and stay on the therapies that matter most for their health.”

Repatha is a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor injection originally approved by the FDA in 2015. It has since been used by 6.7 million patients across 74 countries, including the United States.

Repatha is currently approved:

On its own:

• to reduce the risk of major cardiovascular events in adults, such as heart attack or stroke

As an adjunct therapy, in addition to diet and exercise in:

• adults with hypercholesterolemia
• adults and pediatric patients ages 10 and older with heterozygous familial hypercholesterolemia
• adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia

The latest indication was approved by the FDA in Aug. 2025 for adults at an increased risk for major adverse cardiovascular events due to uncontrolled low-density lipoprotein cholesterol (LDL-C).

Scientists are also currently studying the effectiveness of adding Repatha to a standard therapy of statins to lower the likelihood of cardiovascular events.

The full results will be presented at the American Heart Association Scientific Sessions on Nov. 8 as part of the "Groundbreaking Trials in Cardiometabolic Therapeutics” session.

Cardiovascular disease is the leading cause of death in the United States, where someone has a heart attack approximately every 40 seconds. Additionally, heart disease is expensive—accounting for a loss of approximately $418 billion from 2020 to 2021. This accounts for variables such as the cost of health care services, medication and productivity losses from death.

"Repatha has already helped more than 5 million patients, and the AmgenNow program will make it easier for uninsured patients or those who choose to pay out-of-pocket to access treatment,” Murdo Gordon, executive vice president of Global Commercial Operations at Amgen, said in a news release. “This will allow even more Americans at increased risk of major adverse cardiovascular events to benefit from this effective medicine."

The popularity of direct-to-patient models such as AmgenNow has been increasing due to their convenience and surging drug prices. Medications are typically prescribed online during a telehealth appointment and then shipped directly to the patient.

Other companies that offer deals include Bristol Myers Squibb, which will offer Sotyktu (deucravacitinib) at more than 80% off the current list price, which is $606, and Accord BioPharma, which offers discounted, prefilled syringes of Imuldosa (ustekinumab-srlf), a Stelara (ustekinumab) biosimilar, for 92% off the list price of Stelara, which is currently $25,497.12 every eight weeks.